1. Home
  2. PAYS vs APMD Comparison

PAYS vs APMD Comparison

Compare PAYS & APMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paysign Inc.

PAYS

Paysign Inc.

N/A

Current Price

$9.40

Market Cap

780.3M

ML Signal

N/A

Logo Apnimed Inc. Common Stock

APMD

Apnimed Inc. Common Stock

N/A

Current Price

$16.65

Market Cap

895.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PAYS
APMD
Founded
2001
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
780.3M
895.5M
IPO Year
2020
2026

Fundamental Metrics

Financial Performance
Metric
PAYS
APMD
Price
$9.40
$16.65
Analyst Decision
Buy
Strong Buy
Analyst Count
5
4
Target Price
$14.81
★ $50.33
AVG Volume (30 Days)
★ 1.2M
346.0K
Earning Date
11-09-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 85.71
N/A
EPS
★ 0.30
N/A
Revenue
★ $24,120,434.00
N/A
Revenue This Year
$40.90
$136.18
Revenue Next Year
$12.70
N/A
P/E Ratio
$31.48
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$3.08
$13.88
52 Week High
$16.15
$35.29

Technical Indicators

Market Signals
Indicator
PAYS
APMD
Relative Strength Index (RSI) 26.49 44.15
Support Level $8.26 $16.43
Resistance Level $14.06 $19.83
Average True Range (ATR) 1.17 1.52
MACD -0.68 0.28
Stochastic Oscillator 3.13 46.55

Price Performance

Historical Comparison
PAYS
APMD

About PAYS Paysign Inc.

PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The The company generates revenues from pharma card programs through card program management fees, transaction claim processing fees, interchange fees, customer service fees, other billable service fees and settlement income and other revenues are generated through cardholder fees, interchange fees, program management fees, load fees and breakage.

About APMD Apnimed Inc. Common Stock

Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).

Share on Social Networks: